Eric D. Shaff

Eric D. Shaff

Former President and Chief Executive OfficeratSeres Therapeutics· In proxies 2022–2025

Pay in FY2025-34% from the year before · Seres Therapeutics stock -10.5% the same year

Eric D. Shaff was paid $1.8M in FY2025 (Dec), down 34%. Seres Therapeutics stock fell 10.5% that year.

Pay$100 in the stock at the end of FY21 → $9
Pay is from the Summary Compensation Table of each Seres Therapeutics proxy. The stock line is the value of $100 put in the stock at the start, from the price change of each fiscal year. Dividends are not in it.

Experience

  1. Seres TherapeuticsPublic company · 4 yr
    • Former President and Chief Executive Officer2022 – Present · 4 yrStock in role -99%
  2. Sigilon Therapeutics, Inc.Public company · 6 yr
    • Director2017 – 2023 · 6 yrNo stock prices for these years

Roles come from the proxy statements of each company.

Activity

For the press:Download CSVDownload PNGHow to use our data

Two people shown as one, or a wrong number?